FeesSafety
Pluang+

Daily oral elraglusib shows up to 77% tumor growth inhibition in aggressive melanoma preclinical study

Market News
18 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Daily oral elraglusib shows up to 77% tumor growth inhibition in aggressive melanoma preclinical study

Actuate Therapeutics reported that daily oral dosing of elraglusib achieved up to 77% tumor growth inhibition in a preclinical aggressive melanoma model, with higher drug exposure linked to greater antitumor effects. The treatment also improved the tumor immune environment by increasing cytotoxic T cells and natural killer cells while reducing immunosuppressive myeloid cells. These promising preclinical results support the initiation of a Phase 1/2 clinical trial starting in Q1 2027 to evaluate elraglusib as a daily oral therapy for refractory metastatic melanoma. The shift from intermittent IV dosing to continuous oral dosing aims to sustain drug exposure and enhance antitumor activity.

Actuate Therapeutics' elraglusib shows promising preclinical results in aggressive melanoma. For readers following the health sector, here is Pluang's market snapshot as of Nov 18, 2026 19:21 WIB: out of 150 priced US health stocks, 55 rose and 86 fell. Notable movers include FLNA at USD 0.47 with a 1-day change of -2.22% and 97% sell order activity, TNGX at USD 22.60 up 2.22%, and CTXR at USD 0.53 up 2.16% with 90% sell order activity.

More News

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's reported adjusted earnings per share of $3.10, surpassing estimates of $2.88, and revenue of $22.80 billion, beating the $22.40 billion forecast. Comparable sales rose 1.8%, driven by strong online and professional services sales. The company ...

Company Fundamentals
Bullish
49 minutes ago
Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
54 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App